-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The apolipoprotein E4 (APOE ε4) allele is the main genetic risk factor for late-onset Alzheimer's disease (AD)
.
However, even among APOE ε4 carriers older than 90 years2, not all APOE ε4 carriers develop dementia
The increase of CRP in the blood is only related to the increased risk of AD in carriers of APOE ε4 allele, which indicates that CRP may change the role of APOE ε4, leading to AD-related neurodegeneration
.
Nevertheless, the interaction of APOE ε4 and CRP on cognitive decline and AD pathology is still unknown
The interaction of APOE ε4 and CRP on cognitive decline and AD pathology is still unknown
Immune heart blood vessels
In this way, Qiushan Tao et al.
of Boston University School of Medicine used the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort to explore the APOE ε4 status (none, one and two APOE ε4 alleles) and peripheral CRP recognition.
Know the independent and interactive effects of AD biomarkers in vivo, including cerebrospinal fluid (CSF) amyloid β peptide 42 (Aβ42), total tau (t-Tau) and phosphorylated tau (p-Tau)
.
They analyzed data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study, including APOE genotype; plasma CRP concentration; diagnostic status (ie
.
dementia due to MCI and AD); mini mental status examination (MMSE) and clinical dementia Scoring (CDR) dementia staging tool; the concentration of amyloid β peptide (Aβ42), total tau (t-tau) and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF); and amyloid (AV45) PET imaging
diagnosis
Of the 566 ADNI participants, 274 (48.
4%) did not have one, 222 (39.
2%) had one, and 70 (12.
4%) had two APOEε4 alleles
.
Only in participants with two APOE ε4 alleles, increased CRP was associated with decreased MMSE at baseline and 12-month follow-up
.
The increase in CRP is related to the decrease in MMSE at baseline and 12-month follow-up.
The interaction between the two APOE ε4 alleles and the increase in plasma CRP is associated with t-Tau (β = 11.
21, SE = 3.
37, p <0.
001) and p-Tau (β = +2.
74, SE = 1.
14, p < 0.
01) is related to the increase in the level
.
In people without the APOE ε4 allele, an increase in CRP is associated with a decrease in CSF t-Tau and p-Tau
The important significance of this study is that the CRP released during peripheral inflammation may be a mediator of APOE ε4-related AD neurodegeneration, and can be used as a drug target for AD
.
.
CRP released during peripheral inflammation may be a mediator of APOE ε4-related AD neurodegeneration, and can be used as a drug target for AD
Leave a message here
